MedTrace Logo

Outbreak of Hemolytic Uremic Syndrome Linked to Escherichia Coli of Serotype O104:H4

NCT01406288 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 9

Last updated 2012-11-20

No results posted yet for this study

Summary

The Hemolytic Uremic Syndrome (HUS) in its typical form occurs after a food born infection with a shiga-toxin secreting bacteria, usually Escherichia coli of the O157H7 serotype. An outbreak of bloody diarrhea followed by HUS begun after a collective meal with 120 persons on June 8th, 2011 in Bègles, a city of Bordeaux urban area (CUB).

At least 9 patients, 8 adults and 1 child have been involved in this HUS outbreak, E. coli of the O104:H4 serotype being demonstrated in most patients. This outbreak is remarkable by its preponderance in adults and women, its aggressiveness with multiorgan involvement , i.e. the kidneys, brain, liver, pancreas, and skin.

Pathophysiology, prognosis, and treatment of typical HUS are poorly defined, particularly in adults who are usually not involved in typical E. coli O157H7 HUS.

The aim of the present study is to gain knowledge on these different aspects of the HUS, including response to therapy.

Conditions

  • Hemolytic-uremic Syndrome
  • Escherichia Coli Infections

Interventions

OTHER

HUS standard coverage care (including in ICU)

HUS standard coverage care : plasmaphereses - eculizumab - Immunoadsorption

Sponsors & Collaborators

  • University Hospital, Bordeaux

    lead OTHER

Principal Investigators

  • christian COMBE, MD · University Hospital, Bordeaux

  • Christian COMBE, MD · University Hospital, Bordeaux

Eligibility

Min Age
2 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-07-31
Primary Completion
2012-03-31
Completion
2012-03-31

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01406288 on ClinicalTrials.gov